

This listing of claims will replace all prior versions, and listings, of claims in the application.

Listing of Claims:

Claim 1 (Previously amended) A method for treating a gastrointestinal disorder in a mammal suffering from or susceptible to the disorder, the method comprising administering to the mammal a therapeutically effective amount of a compound represented by any one of Formulae I, III, IV and VI through XIII or a pharmaceutically acceptable salt or solvate thereof.

Claim 2 (Canceled)

Claim 3 (Previously amended) The method of claim 1 wherein the mammal has been identified and selected for treatment to increase NO activity, and the compound is then administered to the identified and selected mammal.

Claim 4 (Previously amended) The method of claim 1 wherein the amount of the administered compound is sufficient to increase neuronal cyclic guanosine 3'-monophosphate (cGMP) levels as measured by a standard cGMP assay.

Claim 5 (Currently amended) The method of claim 1 wherein the gastrointestinal disorder is characterized by ~~hypomotility or hypermotility~~ motility disturbances in at least one of small intestine, large intestine, colon, esophagus and stomach.

Claim 6 (Previously amended) The method of claim 1 wherein the gastrointestinal disorder is further characterized by at least one of nausea, vomiting, heartburn, postprandial discomfort, diarrhea, constipation, and indigestion.

Claim 7 (Previously amended) The method of claim 1 wherein the disorder is associated with at least one of diabetes, anorexia nervosa, bulimia, achlorhydria, achalasia, anal fissure, irritable bowel syndrome, intestinal pseudoobstruction, scleroderma and gastrointestinal damage.

Claims 8-12 (Canceled)